Does the media favor LAB or HYFT?

In the previous week, Standard BioTools and Standard BioTools both had 2 articles in the media. Standard BioTools' average media sentiment score of 1.84 beat MindWalk's score of 0.34 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MindWalk 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, HYFT or QSI?

MindWalk has higher revenue and earnings than Quantum-Si. MindWalk is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $11.24M 5.90 -$10.11M -$0.22 N/A Quantum-Si $2.44M 76.01 -$101.34M -$0.46 N/A

Is HYFT or QSI more profitable?

MindWalk has a net margin of -89.65% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -89.65% -92.61% -54.15% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media favor HYFT or QSI?

In the previous week, Quantum-Si had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Quantum-Si and 2 mentions for MindWalk. Quantum-Si's average media sentiment score of 0.78 beat MindWalk's score of 0.34 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HYFT or CDXS?

MindWalk has higher earnings, but lower revenue than Codexis. MindWalk is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $11.24M 5.90 -$10.11M -$0.22 N/A Codexis $70.39M 2.61 -$43.97M -$0.34 N/A

Is HYFT or CDXS more profitable?

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -89.65%. Codexis' return on equity of -74.36% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -89.65% -92.61% -54.15% Codexis -39.55% -74.36% -23.58%

Does the media refer more to HYFT or CDXS?

In the previous week, Codexis had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Codexis and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.34 beat Codexis' score of 0.14 indicating that MindWalk is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, QTRX or HYFT?

MindWalk has lower revenue, but higher earnings than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 0.95 -$107.15M -$2.63 N/A MindWalk $11.24M 5.90 -$10.11M -$0.22 N/A

Is QTRX or HYFT more profitable?

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -89.65%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -80.25% -26.09% -19.03% MindWalk -89.65% -92.61% -54.15%

Which has stronger valuation & earnings, HYFT or MXCT?

MindWalk has higher earnings, but lower revenue than MaxCyte. MindWalk is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $11.24M 5.90 -$10.11M -$0.22 N/A MaxCyte $33.03M 4.22 -$44.63M -$0.33 N/A

Is HYFT or MXCT more profitable?

MindWalk has a net margin of -89.65% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -89.65% -92.61% -54.15% MaxCyte -114.77% -18.92% -16.14%

Does the media favor HYFT or MXCT?

In the previous week, MaxCyte had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for MindWalk. MaxCyte's average media sentiment score of 0.86 beat MindWalk's score of 0.34 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MindWalk (HYFT) Competitors

$1.42 +0.04 (+2.90%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.42 +0.00 (+0.28%)

As of 04:01 AM Eastern

Compare

HYFT vs. LAB, QSI, CDXS, QTRX, and MXCT

Should you buy MindWalk stock or one of its competitors? MindWalk's main competitors and comparable companies include Standard BioTools (LAB), Quantum-Si (QSI), Codexis (CDXS), Quanterix (QTRX), and MaxCyte (MXCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MindWalk compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Standard BioTools has a net margin of 100.36% compared to MindWalk's net margin of -89.65%. Standard BioTools' return on equity of -7.57% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
MindWalk	-89.65%	-92.61%	-54.15%

Standard BioTools presently has a consensus target price of $1.35, suggesting a potential upside of 107.69%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 252.11%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Standard BioTools has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

MindWalk has lower revenue, but higher earnings than Standard BioTools. MindWalk is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	2.99	-$74.90M	$0.22	2.95
MindWalk	$11.24M	5.90	-$10.11M	-$0.22	N/A

In the previous week, Standard BioTools and Standard BioTools both had 2 articles in the media. Standard BioTools' average media sentiment score of 1.84 beat MindWalk's score of 0.34 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Standard BioTools beats MindWalk on 10 of the 16 factors compared between the two stocks.

How does MindWalk compare to Quantum-Si?

MindWalk (NASDAQ:HYFT) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

MindWalk has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.24, suggesting that its share price is 224% more volatile than the broader market.

In the previous week, Quantum-Si had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Quantum-Si and 2 mentions for MindWalk. Quantum-Si's average media sentiment score of 0.78 beat MindWalk's score of 0.34 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MindWalk presently has a consensus price target of $5.00, indicating a potential upside of 252.11%. Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 18.02%. Given MindWalk's stronger consensus rating and higher possible upside, equities research analysts clearly believe MindWalk is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 22.0% of Quantum-Si shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MindWalk has a net margin of -89.65% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

MindWalk has higher revenue and earnings than Quantum-Si. MindWalk is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24M	5.90	-$10.11M	-$0.22	N/A
Quantum-Si	$2.44M	76.01	-$101.34M	-$0.46	N/A

Summary

Quantum-Si beats MindWalk on 9 of the 17 factors compared between the two stocks.

How does MindWalk compare to Codexis?

MindWalk (NASDAQ:HYFT) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 252.11%. Codexis has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -89.65%. Codexis' return on equity of -74.36% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Codexis	-39.55%	-74.36%	-23.58%

MindWalk has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Codexis has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

MindWalk has higher earnings, but lower revenue than Codexis. MindWalk is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24M	5.90	-$10.11M	-$0.22	N/A
Codexis	$70.39M	2.61	-$43.97M	-$0.34	N/A

In the previous week, Codexis had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Codexis and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.34 beat Codexis' score of 0.14 indicating that MindWalk is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Codexis beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Quanterix?

Quanterix (NASDAQ:QTRX) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, MindWalk had 1 more articles in the media than Quanterix. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for Quanterix. MindWalk's average media sentiment score of 0.34 beat Quanterix's score of -0.35 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Quanterix	Neutral
MindWalk	Neutral

Quanterix has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

MindWalk has lower revenue, but higher earnings than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.95	-$107.15M	-$2.63	N/A
MindWalk	$11.24M	5.90	-$10.11M	-$0.22	N/A

Quanterix presently has a consensus price target of $3.00, indicating a potential upside of 7.53%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 252.11%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -89.65%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
MindWalk	-89.65%	-92.61%	-54.15%

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

MindWalk beats Quanterix on 10 of the 17 factors compared between the two stocks.

How does MindWalk compare to MaxCyte?

MindWalk (NASDAQ:HYFT) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, MaxCyte had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for MindWalk. MaxCyte's average media sentiment score of 0.86 beat MindWalk's score of 0.34 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.7% of MindWalk shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MindWalk has higher earnings, but lower revenue than MaxCyte. MindWalk is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24M	5.90	-$10.11M	-$0.22	N/A
MaxCyte	$33.03M	4.22	-$44.63M	-$0.33	N/A

MindWalk has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 252.11%. MaxCyte has a consensus price target of $5.00, indicating a potential upside of 270.37%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MindWalk has a net margin of -89.65% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
MaxCyte	-114.77%	-18.92%	-16.14%

Summary

MaxCyte beats MindWalk on 9 of the 17 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.46M	$10.16B	$7.35B	$12.72B
Dividend Yield	N/A	1.46%	2.53%	11.02%
P/E Ratio	-6.45	63.32	270.96	24.14
Price / Sales	5.90	110.78	642.82	101.63
Price / Cash	N/A	26.94	78.57	53.12
Price / Book	7.89	37.57	13.14	6.25
Net Income	-$10.11M	$56.67B	$3.46B	$347.86M
7 Day Performance	-2.07%	1.68%	1.51%	0.98%
1 Month Performance	4.41%	10.79%	8.80%	5.24%
1 Year Performance	N/A	25.57%	26.08%	17.04%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	2.9397 of 5 stars	$1.42 +2.9%	$5.00 +252.1%	N/A	$64.46M	$11.24M	N/A	80
LAB Standard BioTools	3.9334 of 5 stars	$0.66 +1.3%	$1.35 +106.1%	-47.6%	$257.14M	$85.33M	2.98	620	Positive News
QSI Quantum-Si	2.7069 of 5 stars	$0.89 +13.6%	$1.00 +12.9%	-25.7%	$192.91M	$2.44M	N/A	150	Gap Up
CDXS Codexis	3.9226 of 5 stars	$1.61 +1.6%	$6.50 +305.0%	-37.3%	$175.76M	$77.68M	N/A	250
QTRX Quanterix	1.1008 of 5 stars	$3.06 -1.9%	$3.00 -2.0%	-40.3%	$144.71M	$138.90M	N/A	460	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. LAB, QSI, CDXS, QTRX, and MXCT

How does MindWalk compare to Standard BioTools?

Summary

How does MindWalk compare to Quantum-Si?

Summary

How does MindWalk compare to Codexis?

Summary

How does MindWalk compare to Quanterix?

Summary

How does MindWalk compare to MaxCyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. LAB, QSI, CDXS, QTRX, and MXCT

How does MindWalk compare to Standard BioTools?

Is LAB or HYFT more profitable?

Do analysts recommend LAB or HYFT?

Do institutionals and insiders hold more shares of LAB or HYFT?

Which has more volatility and risk, LAB or HYFT?

Which has higher earnings & valuation, LAB or HYFT?

Does the media favor LAB or HYFT?

Summary

How does MindWalk compare to Quantum-Si?

Which has more volatility & risk, HYFT or QSI?

Does the media favor HYFT or QSI?

Do analysts prefer HYFT or QSI?

Do insiders & institutionals believe in HYFT or QSI?

Is HYFT or QSI more profitable?

Which has stronger earnings & valuation, HYFT or QSI?

Summary

How does MindWalk compare to Codexis?

Do analysts rate HYFT or CDXS?

Do insiders and institutionals hold more shares of HYFT or CDXS?

Is HYFT or CDXS more profitable?

Which has more volatility & risk, HYFT or CDXS?

Which has higher earnings and valuation, HYFT or CDXS?

Does the media refer more to HYFT or CDXS?

Summary

How does MindWalk compare to Quanterix?

Does the media prefer QTRX or HYFT?

Which has more risk and volatility, QTRX or HYFT?

Which has higher valuation & earnings, QTRX or HYFT?

Do analysts prefer QTRX or HYFT?

Is QTRX or HYFT more profitable?

Do institutionals and insiders have more ownership in QTRX or HYFT?

Summary

How does MindWalk compare to MaxCyte?

Does the media favor HYFT or MXCT?

Do insiders & institutionals believe in HYFT or MXCT?

Which has stronger valuation & earnings, HYFT or MXCT?

Which has more risk & volatility, HYFT or MXCT?

Do analysts rate HYFT or MXCT?

Is HYFT or MXCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools